IMC-1 for Fibromyalgia: The Viral Trigger Theory, Latest Trial Status, and What it Means for Patients

THE LATEST NEWS: WHERE IS IMC-1 NOW? (as of October 2025)

Key Updates: The Status of IMC-1 (Dogwood Therapeutics)

The story of IMC-1 is one of the most exciting in fibromyalgia research because it doesn't just treat the pain; it tries to get to the root cause of why we feel sick.

To give you the clearest picture of where this potential treatment stands, here is a breakdown of the most important changes and what they mean for the fibromyalgia community:

Drug Developer Name Change

• Key Update: The company running the clinical trials has changed its name to Dogwood Therapeutics.

• What This Means for You: This is mostly a business-side change. It confirms that the research is still moving forward, but it's important context if you see different company names mentioned in old versus new articles.

Clinical Trial Status (Phase 3)

• Key Update: The drug's development is officially Ready for Phase 3. The FDA has reviewed and accepted the plan for the final, largest trials.

• What This Means for You: This is a good sign for the drug's safety and effectiveness so far. However, the trial is currently stalled because Dogwood Therapeutics is actively seeking a partner (another large pharmaceutical company) to help fund the massive cost of Phase 3 trials. It's ready to go, but they need the funding to proceed.

Current Availability

• Key Update: IMC-1 is not on the market and is not currently available to the public.

• What This Means for You: You cannot get this drug yet. Access will only be possible for people who enroll in the future Phase 3 clinical trials, once those trials secure funding and begin.

---

The Viral Trigger Theory: A Simple Explanation

This is the most intriguing part of IMC-1. It tackles fibromyalgia by asking: What if an old, "sleeping" virus is causing all this trouble?

The Sleeping Virus Analogy

Think of it this way: Almost every person has an old virus, like the one that causes cold sores (Herpes Simplex Virus 1, or HSV-1), sleeping quietly in their body. It's not usually a problem.

The IMC-1 theory suggests that in people with fibromyalgia, this sleeping virus wakes up just enough to cause chaos:

1. The Alarm Goes Off: When you are under stress, get sick, or have surgery, this virus starts to stir.

2. The Immune System Panics: Your body's defense system sees the stirring virus and goes into a state of chronic panic—like a fire alarm that never turns off.

3. The Pain Switch: This constant, low-level immune stress is what researchers believe over-sensitizes your nerves, turning on the widespread pain and deep fatigue we know as fibromyalgia.

How IMC-1 Fights Back

IMC-1 is a combination of two established medicines:

• Famciclovir: This is a strong antiviral drug designed to force the sleeping virus back to sleep.

• Celecoxib: This is an anti-inflammatory drug that also helps stop the virus from waking up, while calming the chronic panic your immune system is in.

The goal is simple: turn off the alarm so your body can finally rest and heal.

---

Trial Results: The Good News and the Catch

IMC-1 has gone through big tests, but the results were mixed:

• The Good News: In earlier trials, the drug showed that it could significantly reduce pain, fatigue, and anxiety. This is why the FDA gave it the special "Fast Track" status.

• The Catch: In the final Phase 2 trial, when they looked at all patients, the drug missed its main goal.

• The Big Discovery: Researchers found a pattern: the drug worked really well for patients who were new to clinical trials. It didn't work as well for patients who had been on lots of different drugs and in many past studies.

This discovery is a huge step forward! It taught the company that IMC-1 is likely most effective for a specific group of patients, and the new Phase 3 trials will focus on those people.

---

What This Means for You Right Now (The Patient Takeaway)

IMC-1 offers hope because it's one of the few drugs trying to treat the cause—a viral trigger—rather than just masking the symptoms.

I find this theory so validating. It gives us a reason for the fatigue that isn't just 'in our heads' and we all know it is NOT in our heads.

My Advice While We Wait: Since IMC-1 isn't available, focus on supporting your immune system right now. 

Good sleep, stress reduction, and targeted vitamins (like magnesium or Vitamin D) can help keep your body balanced. 

If the IMC-1 theory is right, a strong immune system is your best defense!

Big News for the Fibromyalgia Community: A New FDA-Approved Treatment Is Here

 

After more than 15 years without new treatment options, there’s finally a breakthrough: the U.S. Food and Drug Administration (FDA) has approved Tonmya™, a new medication specifically for fibromyalgia.

What Is Tonmya?

Tonmya (cyclobenzaprine HCl) is a non-opioid, once-daily tablet that you take under the tongue at bedtime. It’s designed to absorb quickly and help reduce pain while also targeting one of fibromyalgia’s most stubborn symptoms: nonrestorative sleep—that feeling of waking up tired no matter how long you’ve slept.

What Did the Research Show?

Tonmya was tested in three major clinical trials involving over 1,400 people with fibromyalgia. The results were promising:

• People taking Tonmya reported significant reductions in daily pain compared to those taking a placebo.

• Many participants experienced a 30% or greater improvement in pain after three months.

• The medication was generally well tolerated. Some reported mild side effects like mouth numbness, dry mouth, drowsiness, or canker sores.

Why This Matters

Fibromyalgia affects over 10 million adults in the U.S., most of whom are women. It’s a complex condition that causes widespread pain, fatigue, sleep issues, and cognitive challenges. For years, treatment options have been limited and often ineffective. Tonmya’s approval offers renewed hope for those who’ve felt unheard and underserved.

As Dr. Sharon Waldrop, a person living with fibromyalgia, shared:

“This approval is a promising step forward and brings renewed hope to millions.”

When Will It Be Available?

Tonmya is expected to be available in the U.S. by late 2025. If you’re interested in learning more or speaking with your healthcare provider, you can visit Tonix Pharmaceuticals.

If you’ve been living with fibromyalgia and feeling like nothing helps, this news might feel like a small light at the end of a long tunnel. It’s okay to feel cautious, curious, or even hopeful. You deserve options, and you deserve care that sees the full picture of your experience.

FIBRO FILES: Fibro in the media this week.

Chronic Pain May Be Effectively Treated Using Placebo Effect: 60 patients with osteoarthritis and 79 patients with fibromyalgia as well as 98 healthy individuals were given an inert cream to be applied on their forehand. Pavankumar Kamat, 

July 16, 2020, Medscape.

Cancer and Fibromyalgia: Addressing the Needs of Patients Despite Limited Research. Mary Hanley, LMSW CancerCare, July 15, 2020, Oncology Nurse Advisor. Having either cancer or fibromyalgia is a challenge that millions of Americans face every year. But how do those with comorbid cancer and fibromyalgia fare? Addressing comorbidity between cancer and fibromyalgia is an emerging, but still lacking, area of research. 

Development for Bedtime Treatment of Fibromyalgia. Tonix Pharmaceuticals. Tonix is developing TNX-102 SL as a potential treatment for the symptoms of Fibromyalgia. It is currently in Phase 3 clinical development. TNX-102 SL targets mechanisms which are associated with disturbed sleep. It is believed that increasing sleep quality in fibromyalgia may facilitate the body's adaptive ability to modulate the perception of pain.

Patients with fibromyalgia, OA, RA at increased risk for self-harm: according to findings published in Arthritis Care & Research. Carrie Beach, July 08, 2020, Healio. 

“Our interest lies in examining and comparing the risk of self-harm in specific rheumatological conditions (ankylosing spondylitis, fibromyalgia, osteoarthritis and rheumatoid arthritis),” James A. Prior, BSc, MSc, PhD, of Keele University, in Staffordshire, UK.

FIBRO FILES: Fibro in the media this week.

I am always fascinated to see what information is being published, in the news media, about Fibromyalgia. I thought you might be interested too.

This week we are travelling around the world from Israel, to Canada and then to Virginia USA to see what is being written about Fibromyalgia (FMS). 
..................................................................................
Fibromyalgia patients to become eligible for state disability stipend.  Chronic condition recognized for purpose of state benefits; rocket-battered southern Israel has seen surge in cases over past few years. TIMES OF ISRAEL. 10 November 2019

SUMMARY: The state will recognize those afflicted with fibromyalgia as disabled especially as the number of people diagnosed with fibromyalgia has increased near the Gaza border.
.................................................................................

Treating fibromyalgia can be like peeling an onion

Fibromyalgia is a very complex health condition that is not well understood or managed within the current medical paradigm, licensed nutritionist Nonie De Long says. NEWMARKETTODAY. ca 16 November 2019 

SUMMARY: Gladys asks a question about fibro and her search for holistic answers and an orthomolecular nutritionist answers.
..................................................................................

Opioid Use Disorder-Related Hospitalization Rates Have Increased for Patients with Most Common Rheumatic Diseases. NEWSWISE. 6 November 2019

SUMMARY: Report on a study that examined hospitalization rates for Opiod Use Disorder in patients with fibromyalgia, gout, osteoarthritis, rheumatoid arthritis, and low back pain.
..................................................................................

Findings Link Gut Bacteria and Fibromyalgia

(Credit: Vladislav Muslakov/Unsplash)

POSTED BY JULIE ROBERT-MCGILL

There are alterations in the bacteria in the gastrointestinal tracts of people with fibromyalgia, report researchers.

Fibromyalgia affects 2-4 percent of the population and has no known cure. Symptoms include fatigue, impaired sleep, and cognitive difficulties, but the disease is most clearly characterized by widespread chronic pain.

“AS PAIN PHYSICIANS, WE ARE FRUSTRATED BY OUR INABILITY TO HELP…”

 As reported in the journal Pain, approximately 20 different species of bacteria were found in either greater or lesser quantities in the microbiomes of participants suffering from the disease than in the healthy control group.

“We used a range of techniques, including artificial intelligence, to confirm that the changes we saw in the microbiomes of fibromyalgia patients were not caused by factors such as diet, medication, physical activity, age, and so on, which are known to affect the microbiome,” says Amir Minerbi of the Alan Edwards Pain Management Unit at the McGill University Health Centre (MUHC), and first author of the paper.

“We found that fibromyalgia and the symptoms of fibromyalgia—pain, fatigue, and cognitive difficulties—contribute more than any of the other factors to the variations we see in the microbiomes of those with the disease,” Minerbi adds.

“We also saw that the severity of a patient’s symptoms was directly correlated with an increased presence or a more pronounced absence of certain bacteria—something which has never been reported before.”

At this point, it’s not clear whether the changes in gut bacteria seen in patients with fibromyalgia are simply markers of the disease or whether they play a role in causing it. Because the disease involves a cluster of symptoms, and not simply pain, the next step in the research will be to investigate whether there are similar changes in the gut microbiome in other conditions involving chronic pain, such as lower back pain, headaches, and neuropathic pain.

The researchers are also interested in exploring whether bacteria play a causal role in the development of pain and fibromyalgia. And whether their presence could, eventually, help in finding a cure, as well as speed up the process of diagnosis.

DIAGNOSIS SOONER?

Fibromyalgia has proved difficult to diagnose. Patients can wait as long as 4 to 5 years to get a final diagnosis. But this may be about to change.

“We sorted through large amounts of data, identifying 19 species that were either increased or decreased in individuals with fibromyalgia,” says Emmanuel Gonzalez, from the Canadian Center for Computational Genomics and the department of human genetics at McGill University.

“By using machine learning, our computer was able to make a diagnosis of fibromyalgia, based only on the composition of the microbiome, with an accuracy of 87 percent. As we build on this first discovery with more research, we hope to improve upon this accuracy, potentially creating a step-change in diagnosis.”

A FRUSTRATING DISEASE

“People with fibromyalgia suffer not only from the symptoms of their disease but also from the difficulty of family, friends, and medical teams to comprehend their symptoms,” says Yoram Shir, the senior author of the paper and the director of the Alan Edwards Pain Management Unit at the MUHC and an associate investigator from the BRaiN Program of the RI-MUHC.

“As pain physicians, we are frustrated by our inability to help, and this frustration is a good fuel for research. This is the first evidence, at least in humans, that the microbiome could have an effect on diffuse pain, and we really need new ways to look at chronic pain.”

The research was based on a cohort of 156 individuals in the Montreal area, 77 of whom suffer from fibromyalgia. Participants in the study participated in interviews and gave stool, blood, saliva, and urine samples, which researchers then compared with those of healthy control subjects, some of whom lived in the same house as the fibromyalgia patients or were their parents, offspring, or siblings.

The researchers’ next steps will be to see whether they get similar results in another cohort, perhaps in a different part of the world, and to do studies in animals to discover whether changes in bacteria play a role in the development of the disease.

Funding for the work came from the Louise and Alan Edwards Foundation and the Israeli Society for Musculoskeletal Medicine. The team also included researchers from McGill University and Université de Montréal, as well as others from the Research Institute of the MUHC.

Source: McGill University

You may also be interested in:

The causes of Fibromyalgia - latest theories (2025)

Upper Trapezius Changes Linked to Fibromyalgia

Identifying Fibromyalgia Biomarkers discovered

Experimental blood test accurately spots fibromyalgia

Study finds unique 'molecular signature' for often-misdiagnosed disease.

Source: Ohio State University

For the first time, researchers have evidence that fibromyalgia can be reliably detected in blood samples – work they hope will pave the way for a simple, fast diagnosis.

In a study that appears in the Journal of Biological Chemistry, researchers from The Ohio State University report success in identifying biomarkers of fibromyalgia and differentiating it from a handful of other related diseases.

The discovery could be an important turning point in care of patients with a disease that is frequently misdiagnosed or undiagnosed, leaving them without proper care and advice on managing their chronic pain and fatigue, said lead researcher Kevin Hackshaw, an associate professor in Ohio State’s College of Medicine and a rheumatologist at the university’s Wexner Medical Center.

Identification of biomarkers of the disease – a “metabolic fingerprint” like that discovered in the new study – could also open up the possibility of targeted treatments, he said.

To diagnose fibromyalgia, doctors now rely on patient-reported information about a multitude of symptoms and a physical evaluation of a patient’s pain, focusing on specific tender points, he said. But there’s no blood test – no clear-cut, easy-to-use tool to provide a quick answer.

“We found clear, reproducible metabolic patterns in the blood of dozens of patients with fibromyalgia. This brings us much closer to a blood test than we have ever been,” Hackshaw said.

Though fibromyalgia is currently incurable and treatment is limited to exercise, education and antidepressants, an accurate diagnosis has many benefits, Hackshaw said. Those include ruling out other diseases, confirming for patients that their symptoms are real and not imagined, and guiding doctors toward disease recognition and appropriate treatment.

“Most physicians nowadays don’t question whether fibromyalgia is real, but there are still skeptics out there,” Hackshaw said.

And many undiagnosed patients are prescribed opioids – strong, addictive painkillers that have not been shown to benefit people with the disease, he said.

“When you look at chronic pain clinics, about 40 percent of patients on opioids meet the diagnostic criteria for fibromyalgia. Fibromyalgia often gets worse, and certainly doesn’t get better, with opioids.”

Hackshaw and co-author Luis Rodriguez-Saona, an expert in the advanced testing method used in the study, said the next step is a larger-scale clinical trial to determine if the success they saw in this research can be replicated.

The current study included 50 people with a fibromyalgia diagnosis, 29 with rheumatoid arthritis, 19 who have osteoarthritis and 23 with lupus.

We found clear, reproducible metabolic patterns in the blood of dozens of patients with fibromyalgia. This brings us much closer to a blood test than we have ever been.

Dr. Kevin Hackshaw

Researchers examined blood samples from each participant using a technique called vibrational spectroscopy, which measures the energy level of molecules within the sample. Scientists in Rodriguez-Saona’s lab detected clear patterns that consistently set fibromyalgia patients’ blood sample results apart from those with other, similar disorders.First, the researchers analyzed blood samples from participants whose disease status they knew, so they could develop a baseline pattern for each diagnosis. Then, using two types of spectroscopy, they evaluated the rest of the samples blindly, without knowing the participants’ diagnoses, and accurately clustered every study participant into the appropriate disease category based on a molecular signature.

“These initial results are remarkable. If we can help speed diagnosis for these patients, their treatment will be better and they’ll likely have better outlooks. There’s nothing worse than being in a gray area where you don’t know what disease you have,” Rodriguez-Saona said.

His lab mostly concerns itself with using the metabolic fingerprinting technology for food-related research, focusing on issues such as adulteration of milk and cooking oils and helping agriculture companies figure out which plants are best suited to fight disease.

The chance to partner with medical experts to help solve the problem of fibromyalgia misdiagnosis was exciting, said Rodriguez-Saona, a professor of food science and technology at Ohio State.

Rodriguez-Saona said for the next study he’d like to examine 150 to 200 subjects per disease group to see if the findings of this research are replicable in a larger, more-diverse population.

Hackshaw said his goal is to have a test ready for widespread use within five years.

Fibromyalgia is the most common cause of chronic widespread pain in the United States, and disproportionately affects women. The U.S. Centers for Disease Control and Prevention estimates that about 2 percent of the population – around 4 million adults – has fibromyalgia. Other organizations estimate even higher numbers.

About three in four people with fibromyalgia have not received an accurate diagnosis, according to previous research, and those who do know they have the disease waited an average of five years between symptom onset and diagnosis. Common symptoms include pain and stiffness all over the body, fatigue, depression, anxiety, sleep problems, headaches and problems with thinking, memory and concentration.

Eventually, this work could lead to identification of a particular protein or acid – or combination of molecules – that is linked to fibromyalgia, Rodriguez-Saona said.

“We can look back into some of these fingerprints and potentially identify some of the chemicals associated with the differences we are seeing,” he said.

In addition to identifying fibromyalgia, the researchers also found evidence that the metabolic fingerprinting technique has the potential to determine the severity of fibromyalgia in an individual patient.

“This could lead to better, more directed treatment for patients,” Hackshaw said.

Other Ohio State researchers involved with the study were Didem Aykas, Gregory Sigurdson, Marcal Plans Pujolras, Francesca Madiai, Lianbo Yu and Monica Giusti. Tony Buffington, formerly of Ohio State and now at the University of California, Davis, was also a co-author.

The research was supported  in part by the Columbus Medical Research Foundation.

6 things that Lady Gaga has said about Fibromyalgia

It's good that Lady Gaga was talking openly about fibromyalgia, don't you think? Here are some things that she has said about living with it...

Living with any chronic pain condition is not fun and to get support for it from people in the limelight is wonderful. I think this is especially true of Fibromyalgia which still has the stigma of not being taken seriously, by many people, even some in the medical profession. When people are in the process of getting a diagnosis we have to tell them to make sure they go to a professional who believes in Fibromyalgia. You don't have to say that about many other conditions!

So when Lady Gaga began talking about having Fibro it felt like the Fibro community around the world was being given validation.

As we would expect from Lady Gaga she was being outspoken about what it's like to live with this chronic pain condition.

In her 2017 documentary Gaga: Five Foot Two we see her in pain and having ice-packs, massages and medications but it is not explained. After the release of the film Lady Gaga tweeted to her fans: "In our documentary the #chronicillness #chronicpain I deal w/ is #Fibromyalgia I wish to help raise awareness & connect people who have it." 12th September 2017.

12th September 2017

12th September 2017 on twitter

In her cover interview for Vogue, in October 2018, Gaga discussed her past trauma and it's affects on her chronic pain. "My diaphragm seizes up. Then I have a hard time breathing, and my whole body goes into a spasm. And I begin to cry," she told the magazine. "That’s what it feels like for trauma victims every day, and it’s . . . miserable. I always say that trauma has a brain. And it works its way into everything that you do."

In the same interview she talked about how people perceive fibromyalgia and other chronic illnesses:

"I get so irritated with people who don't believe fibromyalgia is real. For me, and I think for many others, it's really a cyclone of anxiety, depression, PTSD, trauma, and panic disorder, all of which sends the nervous system into overdrive, and then you have nerve pain as a result," she said. "People need to be more compassionate. Chronic pain is no joke. And it's every day waking up not knowing how you're going to feel."

Quote from Vogue 2018

Quote from Vogue 2018

Quote from Vogue 2018

We hope that Lady Gaga will continue to speak out about Fibromyalgia to help the cause of Fibro. We wish that she would talk about her treatments to help the millions of people who live with it. 

Immune System May Play Role In Fibromyalgia

Researchers have found evidence suggesting the involvement of the immune system in fibromyalgia.

Three molecules that affect the immune system may be associated with the risk of fibromyalgia, according to this research.

These three molecules are called CCL11, CCL4 and MEFV. They are created by inherited mutations in genes.

The study is called “SNPs in inflammatory genes CCL11, CCL4 and MEFV in a fibromyalgia family study.”

SNPs (Single Nucleotide Polymorphisms) are variations in the genetic sequence and are associated with disease. When SNPs occur within a gene or in a regulatory region near a gene, they may play a more direct role in disease by affecting the function of the gene.

The study was approved by the Institutional Review Board of City of Hope National Medical Center, City of Hope, Duarte, CA, United States of America.

Some earlier studies have suggested that there is a genetic component to Fibromyalgia and this study has built on that.

Participants

A total of 220 patients with fibromyalgia and their parents were recruited into the study.

Patients were diagnosed using American College of Rheumatology criteria including musculoskeletal pain that exists for over three months, associated with fatigue, depression, cognitive difficulty and irritable bowel. Patients with rheumatoid arthritis and systemic lupus erythematosus were excluded from the study.

Fibromyalgia (FM) is a chronic pain syndrome with a high incidence in females that may involve activation of the immune system. We performed exome sequencing on chemokine genes in a region of chromosome 17 identified in a genome-wide family association study.

This sequencing on the genes was done on DNA from blood immune cells. Scientists analyzed the four SNPs from parents to fibromyalgia patients, and found only one of them in the CCL11 gene, was associated with a risk of the disease. After further analysis they noted that the levels of CCL11 protein were statistically higher in most of fibromyalgia patients.

“While the elevated expression of CCL11 is a common event, the inability to generate a robust CCL11 response predisposes up to 36% of patients with a higher likelihood of FM."

Conclusions

“This study provides evidence that rs1129844 in CCL11 may be a useful marker for FM and that the high frequency of this SNP in FM patients (36.8%) argues for an underlying immune connection.”

SNPs with significant TDTs were found in 36% of the cohort for CCL11 and 12% for MEFV, along with a protein variant in CCL4 (41%) that affects CCR5 down-regulation, supporting an immune involvement for FM.

Discussion

In summary, we present evidence at both the genetic and functional level that the immune system may be involved in FM in roughly half of a cohort of 220 FM patients for which SNPs in CCL11 and MEFV gave significant TDTs. Considering that activation of the immune system is often associated with neurological systems such as pain, the involvement of the immune system in FM does not rule out the prevailing hypothesis that FM is predominantly a pain syndrome. With this in mind, further studies on larger number of patients may help to validate the link between pain and the immune system in FM.

Fibromyalgia brain study: Findings bring comfort and hope to Fibromyalgia fighters

This research is so important because researchers have found proof that inflammation is happening in Fibromyalgia. It opens many areas for treatments, for validating current treatments and hope for a cure.

"Finding an objective neurochemical change in the brains of people who are used to being told that their problems are imaginary is pretty important," said Marco Loggia, associate director of the Center for Integrative Pain Neuroimaging at Harvard Medical School.

Researchers compared the brain scans of people with fibromyalgia to a healthy control group, and found more inflammation in the immune cells of the brain in people with fibromyalgia.

As Fibromyalgia, does not manifest any structural damage in any organ it is often difficult to prove.  It causes chronic, widespread pain in muscles and soft tissues accompanied by fatigue and sleep disturbances. So this research provides proof that there are physiologic changes that can be found. 

The study used a test called positron emission tomography (PET) which images the brain.

The study and report were quite complex but the findings can be summarized as follows:

1. This research shows that brain levels of the glial marker, TSPO, are elevated in the cortex of FM patients relative to healthy controls. 

This marker of glial activation was increased in several brain regions implicated in FM pathology from previous neuroimaging studies.

2. It also found an association between the TSPO PET signal and fatigue, a predominant FM symptom. 

Various studies have found that patients with Fibromyalgia had elevated levels of  fractalkine and interleukin-8 (IL-8) in cerebrospinal fluid (CSF) (Backryd et al., 2017, Kadetoff et al., 2012, Kosek et al., 2015). Both are implicated in neuron-glial communication and have been associated with central sensitization and pain. But no study had clearly demonstrated that glial activation occurs in the brain of FM patients. Confirming this neuroimmune dysfunction in FM would open the exploration of glial modulation as a therapeutic option for this condition.

Future studies will need to test whether glial modulation may be a viable therapeutic strategy for FM.

Marco Loggia said the results could lead to better ways to see if fibromyalgia treatments, reduce the inflammation that they found. 

These findings may also be an important step in discovering the cause of Fibromyalgia.

It could also help with developing new treatments as the study supports glial modulation as a potential therapeutic strategy for Fibromyalgia.

So this report definitely brings comfort and hope to all of us with Fibro.

FULL REPORT OF STUDY

Fibromyalgia News August 2018

I thought we could do a catch up of all the Fibromyalgia information from August.

It is a roundup of all articles in the news about Fibro (FMS) and all the research released in August about Fibromyalgia.

Just click on the purple links to be taken to the full story.

I hope there is something helpful here for you.

Kirsty Young fibromyalgia: Top treatments to ease pful symptoms

Express.co.uk-30 Aug. 2018

Fibromyalgia, also called fibromyalgia syndrome, is a long-term condition that causes pain all over the body. "Casting away some of the world's most fascinating people is a wonderful job - however, I'm having to take some time away from Desert Island Discs as I'm suffering from a form of fibromyalgia," Young said in a statement.

New 'ultralaser' treatment reduces pain for fibromyalgia patients

Clinical Innovation + Technology-30 Aug. 2018

Fibromyalgia patients experienced significant pain reduction thanks to a new device that uses both ultrasound and laser therapy to help treat the disease, according to a pilot study published in the Journal of Novel Physiotherapies.

Fibromyalgia Worsens Depression, Pain Intensity in Migraine

AJMC.com Managed Markets Network-29 Aug. 2018

Both fibromyalgia and migraine are debilitating pain disorders that have far-reaching impacts on quality of life and can add to the morbidity of the other disorder if both present. Building on prior research drawing a link between migraine and fibromyalgia comorbidity, a new study has found that fibromyalgia exacerbates depressive symptoms, migraine intensity, and migraine-related disability.

Fibromyalgia can be difficult to diagnose, tough to treat

CapeGazette.com-29 Aug. 2018

Q. My sister went through a nightmare of doctor visits before she finally found out she has fibromyalgia. Why did it take so long for a correct diagnosis?

Major ME and fibromyalgia conference set for September International ...

Love Belfast (press release) (blog)-27 Aug. 2018

A major conference on ME and Fibromyalgia is set for September at a time when recruitment is underway for the first ever consultant lead on the condition nears completion.

Hosted by the charity, Hope  4 Me and Fibro Northern Ireland, the event on September 17 at Parliament Buildings, will hear a keynote address from US specialist Jose G Montoya MD of Stanford University.

Fibromyalgia: How Pain Management Doctors Can Help Patients Find ...

Health Essentials from Cleveland Clinic (blog)-21 Aug. 2018

General achiness that changes from day to day. Fatigue. Trouble remembering or concentrating. Headaches. These symptoms may point to fibromyalgia, a chronic disease that affects some 4 million people in the U.S. But they may also point to a number of other conditions, which makes diagnosing and treating fibromyalgia particularly tricky.

Barrie woman's book shares recovery from fibromyalgia

Simcoe.com-18 Aug. 2018

A Barrie woman has used her experience overcoming fibromyalgia and chronic fatigue to help others recover from the illness. Rhonda King’s book, “How I Recovered from Chronic Fatigue Syndrome and Fibromyalgia,” outlines her journey from diagnosis to recovery.

Fibromyalgia Researchers Suggest Moving Away From Tender Point ...

Pain Medicine News-23 Aug. 2018

Rethinking how fibromyalgia is diagnosed may allow for better characterization and understanding of unexplained pain and disability in many ...

Music stars join forces with Connah's Quay man to battle fibromyalgia

LeaderLive-20 Aug. 2018

LAST year pop singer Lady Gaga announced the cancellation of the upcoming leg of her world tour due to her ongoing battle with fibromyalgia ...

Explaining Fibromyalgia: The Switchboard Analogy

Yahoo News-17 Aug. 2018

Having had fibromyalgia for 20 years, I've tried many ways to communicate its impact succinctly, so someone not experiencing it can quickly .

Fibromyalgia is a disease that eludes diagnosis: Can artificial intelligence change that?

Genetic Literacy Project-17 Aug. 2018

There's no tissue damage that explains the pain fibromyalgia patients experience all over their body, and contemporary medicine struggles to treat and even accept an illness where pain seems to be rooted in the mind or brain, rather than a bodily injury.

'Fibromyalgia may win the battle, I will win the war'

Times of India-12 Aug. 2018

Arushi is suffering from a condition called Fibromyalgia, which makes it impossible for her to sit or stand for more than 15 minutes at a stretch.

Comorbid Fibromyalgia Influences Disease Activity, Quality of Life in ...

Rheumatology Advisor-9 Aug. 2018

In patients with axial spondyloarthritis (axSpA), fulfilling the criteria for fibromyalgia had a modest effect on axSpA disease activity measures and quality of life. The investigators sought to explore the extent to which comorbid fibromyalgia is associated with higher disease activity, worse quality of life, and poorer response to TNF inhibitors in patients with axSpA. 

AI can spot the pain from a disease some doctors still think is fake

Quartz-9 Aug. 2018

In the 16 years since Liptan had her illness so summarily dismissed in 2002, there are still those who believe fibromyalgia isn't “real.” When Ginevra Liptan came back to medical school after a year’s leave, she told her favorite professor she’d taken time off to deal with the onset of fibromyalgia. “He rolled his eyes and said, ‘That doesn’t exist,’” says Liptan.

Milnacipran poorly modulates pain in patients suffering from ...

Dove Medical Press-9 Aug. 2018

Introduction: Fibromyalgia is characterized by widespread and chronic pain, and its prevalence is increasing worldwide. Milnacipran, an antidepressant, is often prescribed for fibromyalgia with a possible beneficial effect on central pain modulation.... Conclusion: Milnacipran did not display a significant analgesic effect after 1-month treatment, but the tendency of milnacipran to reactivate Conditioned Pain Modulation in a number of patients must be explored with longer treatment duration in future studies and pleads for possible subtypes of fibromyalgia patients.

Lifting the fog on fibromyalgia

Stuff.co.nz-8 Aug. 2018

"I'm not giving up." The angel always wins. Harris's fibromyalgia gives him no reprieve from pain, whether it's a two or a 10 on the pain scale. Every morning before Ben Harris throws the bed covers off his aching body, his angels and demons go into battle. 

Woman with fibromyalgia 'unable to leave house' after hot tub theft

St Helens Star-9 Aug. 2018

A 24-YEAR-OLD woman with fibromyalgia says she is "unable to leave the house" after thieves stole a hot tub used to ease her pain. Kate Wellens from Grange Park was diagnosed with the condition aged 17, which causes pain all over the body as well as increased sensitivity, fatigue and muscle stiffness.